Research on Ozempic For Teens

GLP-1 medications like Ozempic and Wegovy are everywhere in the news. Now that they've been approved for adolescents, the conversation has gotten more complicated. Here's an honest breakdown of what the science actually shows, and what we still don't know.

 

What Are GLP-1 Medications?

 

GLP-1 receptor agonists mimic a hormone your gut naturally produces after eating. They work by suppressing appetite, slowing digestion, regulating blood sugar, and reducing cravings. The most talked-about is semaglutide, which is sold as Ozempic for diabetes, and Wegovy for weight loss.

 

What the Research Shows for Teens

 

In 2022, the New England Journal of Medicine published a landmark trial of semaglutide in adolescents with obesity:

 

• Teens using semaglutide lost an average of 16.1% of their body weight over 68 weeks

• The placebo group lost only 0.6% on average

• Significant improvements in blood pressure, blood sugar, and cholesterol were also observed

• Side effects were mostly nausea, vomiting, and diarrhea, especially early on

 

What We Still Don't Know

 

• Long-term safety: Teen bodies are still developing. We don't fully know the effects on bone density, reproductive health, or brain development over years of use.

• Weight regain: In adult studies, most weight returns within a year of stopping. We do not know if this is true for teens.

• Psychological effects: How does appetite suppression during adolescence affect long-term relationship with food?

• Access and equity: At over $1,000/month without insurance, these medications are largely inaccessible to lower-income families, which are the same families disproportionately affected by adolescent obesity.

 

The Bottom Line

 

GLP-1 medications represent a genuine breakthrough for teens with severe obesity who haven't responded to lifestyle interventions. They are not magic pills, not for everyone, and come with real and unknown risks. If you're considering them, the conversation should happen with a doctor.